Aug 23, 2024 4:09pm EDT Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
Aug 21, 2024 9:30pm EDT Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares
Apr 25, 2024 8:00am EDT Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
Mar 15, 2024 4:30pm EDT Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Dec 21, 2023 7:30am EST Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients
Sep 12, 2023 7:30am EDT Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
Sep 01, 2023 7:30am EDT Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
